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Abstract 
 
Background Chronic respiratory diseases (CRD) are common, increasing in prevalence, and cause significant 
morbidity and mortality worldwide. However, we have limited knowledge on causes of death of patients with 
CRD in the general population.  
 
Objective We evaluated mortality rates and causes of death over time in CRD patients. 
 
Methods We used linked primary care and mortality data to determine mortality rates and the most common 
causes of death in people with CRD (including asthma, bronchiectasis, chronic obstructive pulmonary disease 
(COPD), and interstitial lung diseases (ILD)) during 2005-2015 in England.  
 
Results We identified 558,888 CRD patients (451,830 asthma, 137,709 COPD, 19,374 bronchiectasis, 10,745 
ILD). The age-standardised mortality rate of patients with CRD was 1,607 per 100,000 persons (asthma=856, 
COPD=1,503, ILD=2,609, bronchiectasis=1,463). CRD mortality was overall 54% higher than the general 
population. One third of CRD patients died from respiratory-related causes. Respiratory-related mortality was 
constant, while cardiovascular-related mortality decreased significantly over time. COPD accounted for the 
majority of respiratory-related deaths (66% overall) in all patient groups except ILD.  
 
Conclusions CRD patients continue to experience substantial morbidity and mortality due to respiratory diseases. 
Disease-modifying intervention strategies are needed to improve outcomes for patients with CRD. 
 
 
 
Key Messages 
 
What is the key question? 
What do patients with chronic respiratory diseases (asthma, bronchiectasis, COPD, interstitial lung disease) die 
from and how have mortality rates changed? 
What is the bottom line? 
Having a CRD carries a high mortality risk, except in asthma. In patients with CRD, there has been no 
improvement in death from respiratory causes. 
 
Why read on? 
This is the largest observational study of chronic respiratory disease patients.  
  
Introduction 
Chronic respiratory diseases (CRD) including asthma, bronchiectasis, chronic obstructive pulmonary disease 
(COPD), and interstitial lung diseases (ILD) are common, increasing in prevalence, and cause significant 
morbidity and mortality worldwide [1-4]. Despite declines in CRD mortality in some specific populations in recent 
years, there has been an overall increase of 30% in CRD mortality in the general population since 1980 [5]. With 
an ageing population, improvements in treatments, and earlier diagnosis, it is not known whether there have been 
changes in the underlying causes of death in patients with CRD over time. 
 
Lung diseases are responsible for 20% of all deaths in the UK,  most due to lung cancer, COPD, and pneumonia 
[6]. The UK has the highest respiratory mortality rate in the Organisation for Economic Co-operation and 
Development (OECD) [7, 8]. While mortality rates for cardiovascular disease (CVD) in the general population 
have fallen in recent years, mortality due to lung diseases has remained constant [6]. These rates have not 
previously been estimated among patients diagnosed with a chronic respiratory disease.  
 
Asthma is a highly prevalent global disease [4], yet there is limited knowledge on their cause of death. Within 
developed countries, asthma-specific mortality (from acute asthma attacks) has steadily declined over the past few 
decades [9], but far less is known about all-cause asthma mortality. The only comprehensive study to address this 
question, looked between 1999 and 2008, in a Canadian provincial health administrative database, and found that 
asthma patients had a lower mortality rate than the general population, and were most likely to die from comorbid 
disorders than their asthma [10].  
 
Bronchiectasis prevalence is a burden in many countries, including the UK, though comprehensive global data 
remains elusive [11-13]. Few previous studies have looked at rates and causes of death in bronchiectasis patients 
[13, 14]. 
 
COPD prevalence and mortality has increased globally since 1990 and carries an especially high disease burden 
in low and middle-income countries [4, 15]. COPD itself is a major cause of mortality for COPD patients, along 
with other respiratory diseases and cancer; it has been reported that one third of patients with COPD die from 
CVD [16-19]. 
 
Few studies investigate ILD as a whole, many studies focus on idiopathic pulmonary fibrosis (IPF), pulmonary 
sarcoidosis, and pneumoconiosis separately. While the incidence of and mortality due to IPF is known to be 
increasing worldwide and in the UK [20-23], there is a paucity of data on incidence and mortality in patients with 
sarcoidosis and pneumoconiosis [5, 23]. 
 
Many studies have investigated respiratory deaths reported on death certificates [4, 6, 17]; however, relying on 
death certificates alone means that a large number of CRD patients are missed. Previous studies have found that 
anywhere between 6-82% of CRD patients have a CRD listed anywhere on their death certificate [14, 21, 24, 25]. 
 
The aims of this study were to calculate the all-cause and disease-specific mortality rates of CRD patients, 
including patients with asthma, bronchiectasis, COPD, and ILD, compared to the general population; as well as 
investigate the temporal pattern of causes of death between 2005 and 2015. 
 
Methods 
Data Sources 
Primary care electronic healthcare records from the Clinical Practice Research Datalink (CPRD), the largest 
validated anonymized source of longitudinal health data including demographic, medical diagnosis, prescription, 
and laboratory test data that has been shown to be representative of the UK population [26, 27]. Mortality and 
population size data from the Office of National Statistics (ONS) for England and Wales [28, 29]. Socioeconomic 
status (SES) measured in relation to patients’ postcodes from the Index of Multiple Deprivation (IMD) [30]. 
 
Study Population 
Patients over the age of 18 with asthma, bronchiectasis, or ILD, and patients over the age of 35 with COPD [31], 
identified in CPRD using pre-specified Read codes, and alive at any time between 1 January 2004 and 31 
December 2015 were included. Patients were considered eligible if they were registered with a practice that 
consents to participate in the record linkage scheme. Follow up began at the latest of the following dates: study 
start date, the patient’s 18th birthday, the date CPRD deemed the submitting general practice was “up to standard” 
(i.e. the practice had passed a number of quality checks and was deemed suitable for research use), the date a 
patient joined the practice or the date of first diagnosis with CRD. Patients were considered to have asthma at time 
of death if their most recent asthma code was within 3 years of their death to distinguish between resolved and 
current disease [32]. 
 
Exposure 
Chronic respiratory disease diagnosis: asthma, bronchiectasis, COPD, or ILD. A validated code list was used to 
identify asthma patients [33]. A validated COPD code list [34] was the basis for our COPD code list (see 
supplement for additional codes). The code lists used to identify bronchiectasis [12] and ILD [35] patients are 
published. 
 
Outcome 
Mortality rate and underlying cause of death from ONS. ONS derives underlying cause of death using standardised 
guidelines from information available on death certificates and coded using The International Statistical 
Classification of Diseases and Related Health Problems 10th Revision (ICD-10) [36]. 
 
Covariates 
Age was measured in years. SES from IMD 2015 data divided into quintiles, where 1- is most deprived [37]. 
Baseline body mass index (BMI; kg/m²) classified as was ‘underweight’ (<18.5), ‘healthy weight’ (18.5-24.9), 
‘overweight’ (25.0-29.9), and ‘obese’ (>30.0). Baseline smoking status was classified as ‘never smoker/not 
recorded’, ‘current smoker’, and ‘former smoker’ [12]. 
 
Statistical Analyses 
All statistical analyses were performed in STATA version 15 (StataCorp LP, College Station, TX, USA). 
 
Mortality Rates 
Using linked CPRD and ONS mortality data, we analysed mortality trends from 2005 to 2015 among people with 
each CRD. We calculated comparative mortality rates in males and females with each CRD in England to 
mortality rates in the general population from ONS data. We calculated the crude all-cause mortality rates by 
calculating the number of deaths in people with each CRD in the CPRD dataset and dividing by the midpoint 
CRD population for that year, then averaging over the 10 year study period. Additionally we calculated mortality 
figures stratified by age, sex, BMI, smoking status, and SES [28, 29]. We then calculated age-standardised (using 
the 2013 European Standard Population) mortality. We compared our results to the ONS published data on all-
cause mortality figures.  
 
Changes in Causes of Mortality 
We investigated all-cause and disease-specific mortality and determined proportions of deaths due to specific 
causes in people with each CRD using the ONS-derived underlying cause of death. Trends in cause of death were 
assessed using Chi-squared tests.  
 
Sensitivity Analyses 
As a sensitivity analysis, we computed trends in causes of death using both ONS-derived underlying cause of 
death and the cause of death as reported in the first position on the death certificate, which may be ill-defined [38]. 
Sensitivity analyses in each of the disease populations was undertaken by examining mortality rates and causes 
of death after excluding patients that had a co-diagnosis of another CRD. 
 
Results 
Cohort Characteristics 
We identified 558,888 CRD patients who met the inclusion and exclusion criteria (Figure 1; S1), of whom 
75,789 died (14%) between 2005 and 2015 (Table 1). Average age at death increased from 77.4 years (95%CI: 
77.2-77.8) in 2005 to 79.2 years (95%CI 78.9-79.4) in 2015. 
 
  
   
Full CRD 
Cohort                                                      
n (%) 
Asthma Cohort                                     
n (%) 
Bronchiectasis           
Cohort                        
n (%) 
COPD Cohort                                          
n (%) 
ILD Cohort                                          
n (%) 
Number of Patients N = 558,888 N = 451,830 N = 19,374 N = 137,709 N = 10,745 
      
Number of Patient Deaths 75,789 (13.6) 27,656 (6.12) 5,446 (28.1) 54,320 (39.4) 5,249 (48.9) 
Length of Follow-Up, years 
(median, IQR) 
3.53 
(1.49, 6.32) 
3.40 
(1.51, 6.26) 
3.32 
(1.33, 6.05) 
3.42 
(1.44, 6.14) 
2.21 
(0.84, 4.39) 
      
      
  
      
Descriptive Statistics of CRD Patient Deaths 
 
Female 36,862 (48.6) 15,313 (55.4) 2,960 (54.4) 24,696 (45.5) 1,874 (35.7) 
  
     
Age at Death, years (mean, SD) 78.4 ± 11.4 76.6 ± 13.5 79.1 ± 10.6 79.1 ± 9.86 78.8 ± 9.61 
     Males 77.4 ± 11.2 75.1 ± 13.6 78.0 ± 10.4 78.3 ± 9.71 78.1 ± 9.13 
     Females 79.4 ± 11.5 77.8 ± 13.3 80.0 ± 10.6 80.0 ± 9.94 79.9 ± 10.3 
  
     
Age Groups at Death 
     
     18-24 years 92 (0.12) 87 (0.31) 5 (0.09) ~ 0 
     25-34 years 253 (0.33) 245 (0.89) 7 (0.13) ~ < 5 
     35-44 years 605 (0.80) 528 (1.91) 28 (0.51) 91 (0.17) 19 (0.36) 
     45-54 years 1,783 (2.35) 1,212 (4.38) 89 (1.63) 735 (1.35) 70 (1.33) 
     55-64 years 5,707 (7.53) 2,472 (8.94) 368 (6.76) 3,823 (7.04) 337 (6.42) 
     65-74 years 15,016 (19.8) 5,196 (18.8) 1,066 (19.6) 11,344 (20.9) 1,076 (20.5) 
     75-84 years 27,472 (36.3) 9,226 (33.4) 2,046 (37.6) 20,776 (38.3) 2,196 (41.8) 
     85+ years 24,861 (32.8) 8,690 (31.4) 1,837 (33.7) 17,551 (32.3) 1,549 (29.5) 
  
     
Smoking Status 
     
     Never Smoker 13,451 (17.8) 8,063 (29.2) 1,920 (35.3) 6,175 (11.4) 1,160 (22.1) 
     Current Smoker 18,720 (24.7) 5,231 (18.9) 594 (10.9) 16,042 (29.5) 521 (9.93) 
     Former Smoker 36,325 (47.9) 12,627 (45.7) 2,517 (46.2) 27,717 (51.0) 2,811 (53.6) 
     Not Recorded 7,293 (9.6)  1,735 (6.3) 415 (7.6) 4,386 (8.1) 757 (14.4) 
  
     
Body Mass Index (kg/m²) (n = 63,909) (n = 24,028) (n = 4,593) (n = 45,874) (n = 4,410) 
     Underweight (< 18.5) 4,738 (7.41) 1,331 (5.54) 546 (11.9) 3,839 (8.37) 203 (4.60) 
     Healthy Weight (18.5-24.9) 24,663 (38.6) 8,567 (35.7) 2,024 (44.1) 18,334 (40.0) 1,587 (36.0) 
     Overweight (25.0-29.9) 19,783 (31.0) 7,654 (31.9) 1,320 (28.7) 13,730 (29.9) 1,671 (37.9) 
     Obese (>= 30) 14,725 (23.0) 6,476 (27.0) 703 (15.3) 9,971 (21.7) 949 (21.5) 
  
     
Diagnosis of Asthma 27,656 (36.5) ~ 1,179 (21.7) 11,870 (21.9) 526 (10.0) 
Diagnosis of Bronchiectasis 5,446 (7.19) 1,179 (4.26) ~ 2,664 (4.90) 379 (7.22) 
Diagnosis of COPD 54,320 (71.7) 11,870 (42.9) 2,664 (48.9) ~ 1,481 (28.2) 
Diagnosis of ILD 5,249 (6.93) 526 (1.90) 379 (6.96) 1,481 (2.73) ~ 
     Diagnosis IPF 896 (1.18) 66 (0.24) 48 (0.88) 206 (0.38) 896 (17.1) 
     Diagnosis Pneumoconiosis 778 (1.03) 82 (0.30) 35 (0.64) 311 (0.57) 778 (14.8) 
     Diagnosis Sarcoidosis 163 (0.22) 22 (0.08) 11 (0.20) 34 (0.06) 163 (3.11) 
  
     
Index of Multiple Deprivation 
     
     1- Most Deprived 12,289 (16.2) 4,926 (17.8) 1,174 (21.6) 7,878 (14.5) 1,066 (20.3) 
     2- 15,147 (20.0) 5,751 (20.8) 1,231 (22.6) 10,352 (19.1) 1,201 (22.9) 
     3- 15,732 (20.8) 5,724 (20.7) 1,060 (19.5) 11,159 (20.6) 1,130 (21.6) 
     4- 15,838 (20.9) 5,670 (20.5) 943 (17.3) 11,886 (21.9) 944 (18.0) 
     5- Least Deprived 16,723 (22.1) 5,569 (20.2) 1,037 (19.0) 12,998 (24.0) 903 (17.2) 
Table 1. Descriptive Statistics of Chronic Respiratory Disease (CRD) Patient Deaths. Presented for those who died in the 
CRD cohort, including patients with asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), and interstitial 
lung disease (ILD). Categorical data are presented as count (percent). Percentages may not sum to 100 due to rounding. Patients 
may be in multiple disease cohorts. IPF = idiopathic pulmonary fibrosis. IQR = interquartile range. SD = standard deviation.   
 
 
Mortality Rates 
The cumulative crude all-cause mortality rate for patients with CRD between 2010 and 2015 was 3,030 per 
100,000 patients (95%CI: 3,022-3,038) (Table 2), with a rate of 0.809 per 100,000 person-years (95%CI: 0.807-
0.811). Crude rates were higher in males, older age groups, and current smokers (S2), as well as among patients 
with lower BMI and those living in the least deprived areas (S3). Age- and sex-adjusted all-cause mortality rates 
(ASMR) increased from 1,332 per 100,000 (95%CI: 1,328-1,335) in 2005 to 2,673 per 100,000 (95%CI: 2,666-
2,680) in 2015 (Figure 2). ASMR among CRD patients were 54% (95%CI: 44 – 64) higher than the general 
population and were higher after excluding patients with comorbid CRD (S4). 
  
N N Deaths Crude Mortality Rate ASMR 
General Population 57,885,413 5,477,290 1,178 (1,177 – 1,178) 867 (867 - 868) 
CRD Patients 558,888 75,789 3,030 (3,022 - 3,038) 1,607 (1,603 - 1,611) 
Asthma 451,830 27,656 1,178 (1,177 – 1,178) 856 (853 - 858) 
Bronchiectasis 19,374 5,446 3,030 (3,022 - 3,038) 1,463 (1,439 - 1,488) 
COPD 137,709 54,320 1,245 (1,241 - 1,248) 1,503 (1,492 - 1,513) 
ILD 10,745 5,249 4,996 (4,925 - 5,066) 2,609 (2,540 - 2,678) 
Table 2. Mortality rates stratified by CRD, 2004 - 2015. Presented for overall CRD cohort and sub-cohorts. Data are 
presented as mortality (95% CI), per 100,000 population. Rates have been calculated by averaging over mid-year population 
estimates for each year. Age standardised mortality rate (ASMR). CRD = chronic respiratory disease including asthma, 
bronchiectasis, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD). 
 
 
Cause of death 
32,664 individuals (43%) had a record of their underlying diagnosed lung disease mentioned as one of the causes 
of death on their death certificates. The leading causes of death among all CRD patients were diseases of the 
respiratory system (32%) (Figure 3; S5), where deaths due to COPD and pneumonia accounted for 79% of all 
respiratory deaths (Table 3). The second most common cause of death was diseases of the circulatory system 
(26%) (Table 3; Figure 3; S5). Neoplasms (24%) were the third leading causes of death (Figure 3; S5), with lung 
cancer accounting for over one-third of cancer deaths (Table 3). The other main causes were mental and 
behavioural disorders/diseases of the nervous system (6%) and diseases of the digestive system (4%) (Figure 3; 
S5). Results were consistent in our sensitivity analyses excluding patients with comorbid respiratory diseases (S6) 
and analysing causes of death as listed in the first position on death certificates (S7). 
 
The proportion of deaths due to respiratory diseases remained steady in the CRD population as a whole, and by 
individual disease, from 2005-2015 (p-trend >0.05) (Figure 4; S8). A significant decrease in the proportion of 
deaths attributed to circulatory disease was seen in the CRD population as a whole, from 30% in 2005 to 23% in 
2015 (Figure 4), and by each individual disease population (S8). Among asthma patients, a small decrease in the 
proportion of respiratory-related deaths was seen over time, in keeping with the increase in the proportion of 
mental disorders (S8). And after considering the age distribution of the population (S9) these trends were most 
prominent among the older age groups. 
 
Discussion 
This is the first and largest study to use an unselected cohort (i.e. non-trial population) of patients with CRD 
(asthma, bronchiectasis, COPD and ILD) diagnosed from their primary care records to assess causes of mortality 
over a 10 year period. Mortality was lowest among patients with asthma, in keeping with the general population, 
but remained high among patients with bronchiectasis, COPD, and ILD. Over a third of deaths were attributed to 
respiratory diseases while a significant decrease in deaths attributed to CVD was observed.  
 
Mortality in CRD patients 
Compared with the general population, CRD patients experienced a 54% higher mortality overall. Only 43% of 
all patients with CRD had their underlying respiratory disease mentioned anywhere on their death certificate. 
Patients with CRD were more likely to die from neoplasms or respiratory illness, but less likely to die of CVD, 
than they were 10 years ago. Over this period, improvements in comorbid disease management, risk stratification, 
and new medications have driven this reduction in CVD deaths, as reflected in the general population [39]. Cancer 
continued to be attributed to a significant proportion of the causes of death among the CRD population, despite a 
decline in the general population [40]. Increased numbers of deaths due to mental and behavioural disorders and 
diseases of the nervous system are likely explained by the ageing population and increased detection, particularly 
observed after the cause of death coding changes in 2010 [41].  
 CRD Asthma Bronchiectasis COPD ILD 
Chapter (ICD-10) 
N 
% of all 
deaths 
% of 
chapter 
N 
% of all 
deaths 
% of 
chapter 
N 
% of all 
deaths 
% of 
chapter 
N 
% of all 
deaths 
% of 
chapter 
N 
% of all 
deaths 
% of 
chapter 
Diseases of the Respiratory 
System (J00-J99) 24,363 32% 100% 6,743 24% 100% 2,235 41% 100% 19,638 36% 100% 2,587 49% 100% 
COPD 16,043 21% 66% 3,935 14% 58% 982 18% 44% 15,164 28% 77% 387 7% 15% 
Pneumonia 3,230 4% 13% 1,285 5% 19% 260 5% 12% 2145 4% 11% 194 4% 7% 
Idiopathic pulmonary fibrosis 1,812 2% 7% 216 1% 3% 133 2% 6% 486 1% 2% 1,568 30% 61% 
Bronchiectasis 853 1% 4% 221 1% 3% 688 13% 31% 461 1% 2% 55 1% 2% 
Asthma 592 1% 2% 463 2% 7% 32 1% 1% 239 0% 1% < 5 0% 0% 
Lung disease due to external agents 551 1% 2% 170 1% 3% 43 1% 2% 371 1% 2% 116 2% 4% 
Influenza 12 0% 0% 8 0% 0% < 5 0% 0% 7 0% 0% 0 0% 0% 
Other 1,270 2% 5% 445 2% 7% 96 2% 4% 765 1% 4% 264 5% 10% 
Diseases of the Circulatory 
System (I00-I99) 19,410 26% 100% 7,778 28% 100% 1,158 21% 100% 13,334 25% 100% 1,062 20% 100% 
Ischaemic Heart Disease 9,565 13% 49% 3,773 14% 49% 547 10% 47% 6,688 12% 50% 603 11% 57% 
Cerebrovascular Disease 4,035 5% 21% 1,626 6% 21% 265 5% 23% 2,706 5% 20% 173 3% 16% 
Heart Failure 971 1% 5% 378 1% 5% 63 1% 5% 665 1% 5% 55 1% 5% 
Other 4,839 6% 25% 2,001 7% 26% 283 5% 24% 3,275 6% 25% 231 4% 22% 
Neoplasms  (C00-D48) 18,341 24% 100% 7,432 27% 100% 995 18% 100% 12,743 23% 100% 872 17% 100% 
Lung Cancer 6,857 9% 37% 2,004 7% 27% 272 5% 27% 5,713 11% 45% 349 7% 40% 
Prostate Cancer 979 1% 5% 384 1% 5% 51 1% 5% 681 1% 5% 56 1% 6% 
Breast Cancer 864 1% 5% 521 2% 7% 64 1% 6% 391 1% 3% 31 1% 4% 
Pancreatic Cancer 774 1% 4% 387 1% 5% 40 1% 4% 471 1% 4% 28 1% 3% 
Bladder Cancer 562 1% 3% 206 1% 3% 37 1% 4% 418 1% 3% 20 0% 2% 
Pleural Mesothelioma 30 0% 0% 14 0% 0% < 5 0% 0% 16 0% 0% < 5 0% 0% 
Other 8,305 11% 45% 3,930 14% 53% 531 10% 53% 12,743 23% 100% 388 7% 44% 
Mental and behavioural 
disorders and Diseases of the 
nervous system (F00-G99) 4,679 6% 100% 1,614 6% 100% 418 8% 100% 3,043 6% 100% 197 4% 100% 
Diseases of the digestive system 
(K00-K93) 3,228 4% 100% 1,477 5% 100% 204 4% 100% 2,103 4% 100% 153 3% 100% 
TOTAL 70,021 92%   25,044 91%   5,010 92%   50,861 94%   4,871 93%   
Table 3. Leading 5 causes of death by underlying CRD. Presented as counts, % of all deaths, and % of deaths within ICD-10 chapter. Values rounded to nearest whole 
number. Patients may be in multiple disease cohorts. CRD = chronic respiratory disease including asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), 
and interstitial lung disease (ILD). ICD-10 chapters F (mental and behavioural disorders) and G (diseases of the nervous system) have been combined.
Mortality in asthma patients 
Asthma patients, those without other respiratory diagnoses, experienced lower all-cause mortality rates compared 
to the general population. Asthma patients with other respiratory diseases experienced high but decreasing all-
cause mortality due to the inclusion of comorbid COPD and patients with a history of smoking suggesting possible 
improvements as awareness of overlap syndromes has increased over time. The most common causes of death in 
all asthma patients were COPD and ischaemic heart disease. After excluding patients with other diagnosed 
respiratory diseases, COPD remained among the leading causes of respiratory-related deaths. This could be due 
to misdiagnosis, related to difficulty in distinguishing clinically between asthma and COPD, or possibly 
misclassification of the  underlying cause of death [42, 43]. 
 
Mortality in bronchiectasis patients 
We observed higher ASMR among patients with bronchiectasis compared to a previous UK study [13]; these rates 
increased after including patients with other CRDs. Bronchiectasis patients were most likely to die from 
bronchiectasis, ischaemic heart disease, and ‘other’ cancers; similar to previous research [12]. Earlier detection of 
bronchiectasis with effective management of exacerbations and reductions in exacerbation frequency may 
decrease excess mortality. 
 
Mortality in COPD patients 
Mortality remained high among COPD patients, similar to previous UK reports [38, 44], but did not reflect the 
decrease presented in previous global estimates [4]. Despite advances in the management of COPD, introduction 
of new therapies, and the publication of new guidelines and strategies [31, 45-47], one-third of deaths among 
COPD patients are still attributed to non-malignant respiratory diseases, mostly COPD, in keeping with previous 
clinical trial data [48]. Just over a quarter of COPD patient deaths were attributed to CVD, less than the one third 
of deaths previously reported [16-19], and possibly related to earlier recognition and better management of CVD 
in the past decade. These results highlight the lack of treatments that reduce respiratory-related mortality and the 
need to pair early diagnosis with effective disease-modifying interventions [49]. 
 
Mortality in ILD patients 
ILD patients experienced increasing high mortality over the study period suggesting increasing incidence or 
increasing case ascertainment of these diseases [50]. This further evidences the typically late stage of ILD at 
diagnosis resulting in poorer prognoses [23, 51]. The leading cause of death among ILD patients remained their 
underlying lung disease, despite being at increased risk for CVD [35]. The increasing availability of anti-fibrotic 
therapies may change this trend in the future [52]. 
 
Strengths 
This study used linked primary care and mortality data to assess cause of death in patients with CRD. Previous 
studies investigating CRD deaths identified patients as those for whom CRD was recorded on their death 
certificate or who were hospitalised [8, 17, 21, 53, 54]. Relying on death certificates alone means that a large 
number of CRD patients may be missed, as previous studies have found that anywhere between 6-82% of CRD 
patients have a CRD listed anywhere on their death certificate, consistent with the 43% we observed [21, 24, 25]. 
This is the first and largest observational study to estimate mortality rates and causes over time using a nationally-
representative cohort of CRD patients. 
 
Another strength of this study is that ONS is nearly 100% complete, with a large proportion of registered deaths 
certified by a medical practitioner, and an ever increasing accuracy of recordings [41]. Since 1993, automated 
coding has been in place for cause of death with application of WHO rules allowing international comparisons 
[55].  While the accuracy of the underlying cause provided by ONS, which is a derived variable, relies on correct 
recording of all contributing causes of death [56];in a review undertaken by ONS, the proposed and medical 
examiner confirmed underlying cause of death matched at ICD chapter level in 88% of cases and there was exact 
agreement (to 4 digits) in 78% of cases, rising to 80% when records matching to 3 digits were included [57]. 
Furthermore, our sensitivity analysis comparing the ONS-derived underlying cause of death to the first listed 
cause of death on the death certificate did not significantly change the proportions of leading causes of death, 
suggesting that the algorithm used to derived cause of death is sufficiently accurate. 
 
Limitations 
One potential limitation of studies using electronic healthcare records is the validity of case definitions. For asthma 
and COPD we used previously validated definitions [33, 34], but there are no validated definitions for ILD and 
bronchiectasis. However, ILD and bronchiectasis diagnoses are made in a secondary care setting and are 
confirmed by computed tomography; it is unlikely that diagnoses of either ILD or bronchiectasis will be recorded 
within primary care without confirmation from secondary care. It is well recognised, as found in our study too, 
that there is a large proportion of patients with overlapping diagnosis of asthma, COPD, and bronchiectasis. Our 
inclusion of these patients reflects clinical practice and explains the large proportion of respiratory deaths 
attributed to COPD. 
 
We were not able to compared mortality rates using person-time of disease as data for the general population were 
obtained via publicly available ONS mortality reports. Therefore morality should be interpreted taking into 
account that duration of disease was not included in estimating mortality rates. In addition we did not include 
details on disease severity or use of medications which may have an impact on overall survival. Future research 
should investigate disease phenotypes with use of interventions to evaluate whether the excess risk of mortality 
we observed is modifiable. Where data were missing in the CRD cohort, categories were either considered missing 
at random or grouped where the number of missing information was low. However there is a possibility that we 
may have misclassified patients. 
 
Conclusions 
This is the largest and most contemporary study to investigate the mortality of CRD patients using a nationally-
representative UK population. All-cause mortality remains high in people with CRD, contrasting to the general 
population. Disease-modifying intervention strategies are needed to improve CRD survival. 
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Figure Legends 
 
Figure 1. Flow chart of patient inclusion. CRD includes asthma, bronchiectasis, chronic obstructive pulmonary 
disease (COPD), and interstitial lung disease (ILD). Disease component numbers do not sum to total numbers as 
patients were able to be part of multiple disease groups. 
 
Figure 2. Age-standardised mortality (ASM) per 100,000 population compared to the general population, 
2005-2015. Presented for all patients with: asthma, bronchiectasis, chronic obstructive pulmonary disease 
(COPD), and interstitial lung disease (ILD). Rates compared to the general population. Groups differentiated as 
‘only’ refer to those patients with that respiratory disease and no other respiratory disease comorbidities. Disease 
group presented are mutually exclusive. pop = population. 
 
Figure 3. Leading Causes of Death among CRD patients by disease. Presented as percentages of all deaths per 
year for the overall CRD and by individual disease; including asthma, bronchiectasis, chronic obstructive 
pulmonary disease (COPD), and interstitial lung disease (ILD). ICD-10 chapters F (mental and behavioural 
disorders) and G (diseases of the nervous system) have been combined. ‘Other’ refers to causes of death 
categorized in all ICD-10 chapters outside of C, D00-48, F, G, I, J, and K. 
 
Figure 4. Trends in leading causes of death in the chronic respiratory disease (CRD) population, 2005-2015. 
Presented as % of all deaths per year for the overall CRD population; including asthma, bronchiectasis, chronic 
obstructive pulmonary disease (COPD), and interstitial lung disease (ILD). ICD-10 chapters F (mental and 
behavioural disorders) and G (diseases of the nervous system) have been combined. ‘Other’ refers to causes of 
death categorized in all ICD-10 chapters outside of C, D00-48, F, G, I, J, and K. Significant p-values (α < 0.05) 
from Chi-squared test for trend are shown. 
 
 
 
